Fidelio acquires Indical Bioscience

April 5, 2018

Fidelio acquires Indical Bioscience, a leading provider of diagnostic products specifically developed for veterinary specific applications.

The company develops and markets diagnostic solutions and products based on PCR (molecular) and ELISA (immunodiagnostic) technology. The products are used by laboratories primarily to indicate and diagnose viruses and bacteria in production animals, to counteract proliferation and contribute to better animal and human health.

Indical Bioscience is based in Germany and serves customers in 169 countries through its own sales force and commercial partners. Fidelio Capital acquired Indical Bioscience through a carve-out from Qiagen, a molecular diagnostic group listed on the NYSE and Frankfurt stock exchanges.

Recent news

Indical acquires Svanova from Boehringer Ingelhei…

Indical has acquired the Svanova product portfolio from Boehringer Ingelheim. Through the acquisition, Indical becomes the exclusive provider of Svanova’s veterinary testing products, which include around 25 livestock ELISA assays. Svanova arose out of the Swedish Veterinary Institute, a pioneer

Read more

PDL expands to Norway

PDL enters Norway by establishing two padel destinations in the Oslo region with 25 padel courts in total. PDL has secured a substantial number of further locations across the country, which are due to open later this year. The expansion

Read more

Fidelio establishes Movora, a global leader in th…

With the formation of Movora, Fidelio establishes a global leader in the veterinary orthopedic market. Movora consists of three brands; Kyon (Switzerland), BioMedtrix (USA) and VOI (USA), acquired by Fidelio during 2019 and 2020. Movora has 8 offices in 5

Read more